

Table S1. Clinicopathological characteristics of D1-D3

	D1 (N=214)	D2 (N=54)	D3 (N=51)	Total (N=319)
Gender				
Male	176 (82.2%)	49 (90.7%)	37 (72.5%)	262 (82.1%)
Female	38 (17.8%)	5 (9.3%)	14 (27.5%)	57 (17.9%)
Age				
Mean (SD)	58.1 (13.5)	61.3 (9.86)	62.0 (7.80)	59.3 (12.3)
BMI				
Mean (SD)	21.6 (2.98)	22.1 (3.03)	25.6 (19.7)	22.3 (8.47)
Missing	4 (1.9%)	3 (5.6%)	0 (0%)	7 (2.2%)
Smoking status				
Never smoked	101 (47.2%)	18 (33.3%)	23 (45.1%)	142 (44.5%)
Current or former smoker	113 (52.8%)	36 (66.7%)	28 (54.9%)	177 (55.5%)
Tumor histologic type				
LUAD	165 (77.1%)	30 (55.6%)	19 (37.3%)	214 (67.1%)
LUSC	49 (22.9%)	24 (44.4%)	32 (62.7%)	105 (32.9%)
Clinical stage				
III	21 (9.8%)	15 (27.8%)	5 (9.8%)	41 (12.9%)
IVA	77 (36.0%)	25 (46.3%)	5 (9.8%)	107 (33.5%)
IVB	116 (54.2%)	14 (25.9%)	41 (80.4%)	171 (53.6%)
Lines of therapy				
First line	65 (30.4%)	40 (74.1%)	45 (88.2%)	150 (47.0%)
Second line or more	149 (69.6%)	14 (25.9%)	6 (11.8%)	169 (53.0%)
ICIs				
anti PD-1	178 (83.2%)	51 (94.4%)	51 (100%)	280 (87.8%)
anti PD-L1	36 (16.8%)	3 (5.6%)	0 (0%)	39 (12.2%)

SD=standard deviation. BMI=body mass index. LUAD=lung adenocarcinoma. LUSC=lung squamous cell carcinoma. LOT=line of therapy. ICIs=immune checkpoint inhibitors. PD-1=programmed death-1. PD-L1=programmed cell death-ligand 1